Arena Pharmaceuticals Inc (ARNA) Stock
ARNA is no longer traded. Arena Pharmaceuticals was acquired by Pfizer (PFE) on March 11, 2022.
Each ARNA share was exchanged for $100.00 in cash. Prices on this page are historical; the last trade was March 10, 2022 at $99.99.
See Pfizer (PFE) stock →Arena Pharmaceuticals stock price history
ARNA final trading statistics
- Final close
- $99.99
- Final trading day
- Mar 10, 2022
- Market cap at delisting
- $6.17B
- Shares outstanding
- 61.66M
- Final 52-week range
- $45.50 – $100.00
- Avg. volume (final 3 mo.)
- 2,005,381
- All-time high (split-adj.)
- $1181.00 · Jul 2012
- All-time low (split-adj.)
- $11.50 · May 2017
- Return since IPO
- -60.0%
- Beta
- 0.55
- Book value / share
- $10.94
- Price / book
- 9.14
Arena Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $54.0K | -$616.4M | -$9.98 |
| FY2020 | $319.0K | -$404.7M | -$7.40 |
| FY2019 | $806.43M | $397.6M | $7.64 |
| FY2018 | $17.97M | -$29.4M | -$0.78 |
| FY2017 | $21.34M | -$91.4M | -$2.56 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Arena Pharmaceuticals Inc
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Arena Pharmaceuticals stock FAQ
What happened to Arena Pharmaceuticals stock?
Arena Pharmaceuticals was acquired by Pfizer (PFE) on March 11, 2022. Shareholders received $100.00 in cash for each share. ARNA stock stopped trading on the Nasdaq, with a final close of $99.99 on March 10, 2022.
What did Arena Pharmaceuticals shareholders receive?
Each ARNA share was converted into $100.00 in cash. The deal was valued at about $6.7 billion.
Is ARNA stock still trading?
No. ARNA was delisted from the Nasdaq on March 11, 2022 and no longer trades on a U.S. exchange.
What was the last price of ARNA stock?
ARNA closed at $99.99 on its final trading day, March 10, 2022, for a market value of about $6.17B.
What were Arena Pharmaceuticals's revenue and earnings in its last full fiscal year?
Arena Pharmaceuticals reported revenue of $54.0K and net income of -$616.4M in fiscal 2021, its last full year as a public company.
When did Arena Pharmaceuticals go public?
Arena Pharmaceuticals Inc stock began trading on July 28, 2000.